818.93
1.30%
-10.81
전일 마감가:
$829.74
열려 있는:
$828
하루 거래량:
4.65M
Relative Volume:
1.53
시가총액:
$782.99B
수익:
$40.86B
순이익/손실:
$8.37B
주가수익비율:
151.11
EPS:
5.4193
순현금흐름:
$-2.28B
1주 성능:
-8.26%
1개월 성능:
-7.41%
6개월 성능:
+5.43%
1년 성능:
+47.70%
일라이 릴리 Stock (LLY) Company Profile
명칭
Lilly Eli Co
전화
(317) 276-2000
주소
LILLY CORPORATE CTR, INDIANAPOLIS, IN
일라이 릴리 Stock (LLY) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-10-17 | 개시 | Bernstein | Outperform |
2024-09-13 | 재개 | Citigroup | Buy |
2024-08-12 | 업그레이드 | Deutsche Bank | Hold → Buy |
2024-02-21 | 다운그레이드 | DZ Bank | Buy → Hold |
2024-02-16 | 재확인 | Morgan Stanley | Overweight |
2023-12-21 | 다운그레이드 | Daiwa Securities | Buy → Outperform |
2023-11-09 | 개시 | Deutsche Bank | Hold |
2023-10-20 | 재개 | UBS | Buy |
2023-08-09 | 업그레이드 | Jefferies | Hold → Buy |
2023-07-26 | 재확인 | Citigroup | Buy |
2023-07-14 | 개시 | HSBC Securities | Buy |
2023-05-24 | 재확인 | BofA Securities | Buy |
2023-05-24 | 재확인 | UBS | Buy |
2023-03-13 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
2023-03-06 | 개시 | Jefferies | Hold |
2023-02-15 | 다운그레이드 | Societe Generale | Hold → Sell |
2022-11-18 | 개시 | Credit Suisse | Outperform |
2022-09-22 | 업그레이드 | UBS | Neutral → Buy |
2022-05-23 | 개시 | SVB Leerink | Outperform |
2022-04-06 | 재개 | Morgan Stanley | Overweight |
2022-03-10 | 개시 | Daiwa Securities | Outperform |
2022-01-21 | 업그레이드 | DZ Bank | Hold → Buy |
2022-01-03 | 재확인 | Bernstein | Mkt Perform |
2021-12-17 | 개시 | Goldman | Neutral |
2021-12-16 | 재확인 | BMO Capital Markets | Outperform |
2021-12-16 | 재확인 | BofA Securities | Buy |
2021-12-09 | 재개 | Wells Fargo | Equal Weight |
2021-11-19 | 개시 | BMO Capital Markets | Outperform |
2021-10-11 | 업그레이드 | Berenberg | Hold → Buy |
2021-09-29 | 업그레이드 | Citigroup | Neutral → Buy |
2021-08-05 | 업그레이드 | DZ Bank | Hold → Buy |
2021-07-27 | 재개 | Truist | Buy |
2021-06-24 | 재확인 | Cantor Fitzgerald | Overweight |
2021-01-19 | 업그레이드 | Mizuho | Neutral → Buy |
2020-12-10 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
2020-11-10 | 재개 | Bernstein | Mkt Perform |
2020-09-29 | 개시 | Berenberg | Hold |
2020-09-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2020-06-16 | 업그레이드 | Guggenheim | Neutral → Buy |
2020-04-21 | 다운그레이드 | UBS | Buy → Neutral |
2020-04-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2020-02-06 | 개시 | Mizuho | Neutral |
2019-12-18 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2019-10-17 | 재개 | BofA/Merrill | Buy |
2019-05-28 | 개시 | Goldman | Buy |
2019-04-24 | 업그레이드 | Edward Jones | Hold → Buy |
2019-04-11 | 다운그레이드 | Guggenheim | Buy → Neutral |
2019-03-12 | 개시 | JP Morgan | Overweight |
2019-01-23 | 개시 | UBS | Buy |
2018-11-26 | 다운그레이드 | Citigroup | Buy → Neutral |
2018-10-31 | 업그레이드 | Credit Suisse | Underperform → Neutral |
2018-10-09 | 개시 | Guggenheim | Buy |
2018-10-01 | 재확인 | SunTrust | Buy |
2018-09-26 | 재개 | JP Morgan | Overweight |
모두보기
일라이 릴리 주식(LLY)의 최신 뉴스
Merus annonce ses résultats financiers pour le troisième trimestre 2024 et fait le point sur ses activités - GlobeNewswire Inc.
Eli Lilly grows Milwaukee-area footprint with $40.8M warehouse acquisition — and more - The Business Journals
Hims & Hers Health Faces Pressure Ahead of Earnings Amid Eli Lilly's GLP-1 News - Yahoo Finance UK
Eli Lilly’s Q3 Miss for Mounjaro, Zepbound Highlights Dependency on Wholesalers - BioSpace
Eli Lilly Stock: Is LLY Stock A Sell After Its Disastrous Third-Quarter Report? - Investor's Business Daily
Why Eli Lilly Is a No-Brainer Stock to Buy on the Dip - MSN
ViaNautis signs multi-year collaboration with Eli Lilly and Company - Business Weekly
Friday Five – Humira humbled, Lilly investors get trick instead of treat, Pfizer seeks to show up Starboard… and more - FirstWord Pharma
Eli Lilly and the British government partner to provide GLP-1 weight loss medication to people who have obesity - HR Brew
Lilly’s earnings surprise, investors mull the election, & a spooky ghost story - STAT
Eli Lilly viewed positively despite Mounjaro, Zepbound disappointmentBoA - Proactive Investors USA
Eli Lilly Shares Hit Yearly Low After Disappointing Q3 Earnings - Yahoo Finance
Eli Lilly and Company (NYSE:LLY): Among The 10 Best S&P 500 Stocks to Buy According to Hedge Funds - Insider Monkey
ELI LILLY AND COMPANY : Jefferies remains its Buy rating - Marketscreener.com
Eli Lilly core thesis ‘remains intact’ despite Q3 miss, says JPMorgan - Yahoo Finance
Are Eli Lilly's Lowered Expectations a Reason to Sell? - The Motley Fool
Eli Lilly and Co (LLY) Q3 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic ... - Yahoo Finance
Eli Lilly and Co (LLY): A Strategic SWOT Insight into Pharma's Future - Yahoo Finance UK
Nasdaq edges back from its record as chip companies and Eli Lilly slump - The Decatur Daily
Stocks hit pause after Nasdaq milestone; Eli Lilly earnings underwhelm Wall St. - The Post and Courier
Health Care Down as Eli Lilly Slides -- Health Care Roundup - MarketWatch
Eli Lilly & Co. stock underperforms Wednesday when compared to competitors - MarketWatch
Stock market today: Nasdaq edges back from its record as chip companies and Eli Lilly slump - Oneonta Daily Star
Wall Street indexes edge lower Wednesday as Alphabet jumps and Eli Lilly slumps - Greater Milwaukee Today | GMToday.com
AMD, Eli Lilly slide; Google, Visa rise among Wednesday's afternoon market cap stock movers - Investing.com
Crude Oil Gains Over 2%; Eli Lilly Cuts 2024 Forecast - Benzinga
Lilly’s Mounjaro, Zepbound drugs see strong demand. So why did sales disappoint? - MarketWatch
Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still disappointed - CNBC
Eli Lilly’s third quarter earnings miss and forecast cut lead to sharp stock drop - LPHeraldDispatch.com
Knockoff weight loss drugs are having a moment. Eli Lilly isn't worried - Yahoo! Voices
Eli Lilly (LLY) Q3 2024 Earnings Call Transcript - The Motley Fool
Eli Lilly plans to begin advertising weight-loss drug Zepbound - Yahoo Finance
Eli Lilly’s slip does not mean the weight loss drug craze is over - Financial Times
Stock movers: Alphabet, Super Micro, Eli Lilly and more - TheStreet
Stock market today: Wall Street wavers as Alphabet jumps on Google profits and Eli Lilly slumps - Ottumwacourier
Eli Lilly had a strong Q3, so why is its stock falling? - Seeking Alpha
Eli Lilly Earnings: Maintaining Our Fair Value and Long-Term GLP-1 Forecast Despite Weaker Q3 - Morningstar
Lilly Cuts Outlook After Obesity Drug Sales Post First Miss - Bloomberg
Eli Lilly's rare sales miss for weight-loss drug sends shares tumbling - Reuters
Eli Lilly: The Stock Might Have Peaked (NYSE:LLY) - Seeking Alpha
Lilly's Q3 Earnings Miss, Mounjaro, Zepbound Disappoint, Stock Tanks - Yahoo Finance
Lilly cuts outlook on surprising weight-loss drug disappointment - Detroit News
Why Eli Lilly Stock Is Sinking Today - The Motley Fool
Lilly shares tumble on earnings report that falls short of Wall Street expectations - Inside INdiana Business
Stock market today: Wall Street churns near records as Alphabet jumps and Eli Lilly slumps - News-Press Now
Eli Lilly shares tumble as company’s weight-loss drug misses Wall Street sales expectations - The Globe and Mail
Have Eli Lilly's weight-loss drug gains hit a plateau? - Sherwood News
Stock market today: Wall Street churns as Alphabet jumps, Eli Lilly tumbles - Ottumwacourier
Drugmaker Eli Lilly dials back 2024 forecast after 3Q earnings miss - WTHR
Drugmaker Eli Lilly walks back 2024 forecast after 3Q earnings miss - Bozeman Daily Chronicle
Eli Lilly stock sinks after Q3 earnings miss Wall Street expectations - Yahoo Finance
일라이 릴리 (LLY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):